Media

October 25, 2023, 4HF Biotec published its work on the dual MEK/AuroraB inhibitor BI 847325 in Cancer Research Communication titled: “High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models” by V. Vuaroqueaux et al.; DOI: https://doi.org/10.1158/2767-9764.CRC-22-0221

April 14 – 19, 2023, 4HF Biotec participated virtually in the AACR Annual Meeting
Our E-Poster in collaboration with Reaction Biology Europe GmbH:
“Introduction of a platform for preclinical profiling of drug conjugates: a case study with sacituzumab govitecan” 
by V. Vuaroqueaux et al.;
Abstract number # 4895

Press Releases

June 09, 2022,  4HF is funded by the state of Baden-Württemberg in the (Invest BW) program for its project SELECTHERA. The project is in partnership with the German Consortium for Translational Cancer Research (DKTK), Freiburg site, and Clinic for Nuclear Medicine, University Freiburg. https://www.dkfz.de/de/presse/pressemitteilungen/2022/dkfz-pm-22-43c-Baden-Wuerttemberg-foerdert-Entwicklung-innovativer-Radiopharmaka.php

https://www.landtag-bw.de/home/aktuelles/pressemitteilungen/2022/juni/912022.html

January 29, 2021, an interview was published on the online news platform GenomeWeb between Vincent Vuaroqueaux of 4HF Biotec and GenomeWeb editor Neil Versel: “4HF Biotec Banking on Multiomic Data Analysis to Help Pharma find new Oncology Compounds”. https://www.genomeweb.com/informatics/4hf-biotec-banking-multiomic-data-analysis-help-pharma-find-new-oncology-compounds

October 19, 2020,  4HF Biotec announced that it entered into a collaboration with Reaction Biology, a drug discovery CRO with offices in Germany and USA, on a new cell-based service offering (Link to PDF)

November, 2019, an article in MIRROR REVIEW was published “4HF BIOTEC: A Novel Approach For Cancer Treatment https://www.mirrorreview.com/4hf-biotec-novel-approach-cancer-treatment/

July, 2019StartupCity selected 4HF Biotec in the top 15 most promising Biotec startups in Europe Links: https://biotech-europe.startupcity.com/vendors/top-biotech-startups-in-europe-2019.html

July 18, 2019,  4HF Biotec announced that it entered into a collaboration with Bionavigen in the field of target and drug discovery (Link to PDF)

Publications

High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models. Vincent Vuaroqueaux, Alexandra Musch, Anne-Lise Peille, Gerhard Kelter, Loreen Weichert, Thomas Metz, Hans R. Hendriks, Heinz-Herbert Fiebig. Cancer Research Communications 3, 10 (2023): 2170–2181, https://doi.org/10.1158/2767-9764.CRC-22-0221

Elevated MACC1 Expression in Colorectal Cancer Is Driven by Chromosomal Instability and Is Associated with Molecular Subtype and Worse Patient Survival. Vuaroqueaux, Vincent, Alexandra Musch, Dennis Kobelt, Thomas Risch, Pia Herrmann, Susen Burock, Anne-Lise Peille, Marie-Laure Yaspo, Heinz-Herbert Fiebig, and Ulrike Stein. 2022 Cancers 14, no. 7: 1749. https://doi.org/10.3390/cancers14071749

Pharmacogenomics characterization of the MDM2 inhibitor MI-773 reveals candidate tumours and predictive biomarkersVuaroqueaux, V., Hendriks, H.R., Al-Hasani, H. et al. npj Precis. Onc. 5, 96 (2021). https://doi.org/10.1038/s41698-021-00235-7

A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia. Andreas Sellmer, Bernadette Pilsl, Mandy Beyer, Herwig Pongratz, Lukas Wirth, Sigurd Elz, Stefan Dove, Sven Julian Henninger, Karsten Spiekermann, Harald Polzer, Susan Klaeger, Bernhard Kuster, Frank D. Böhmer, Heinz-Herbert Fiebig, Oliver H. Krämer, Siavosh Mahboobi. European Journal of Medicinal Chemistry, Volume 193, 2020, 112232, ISSN 0223-5234, https://doi.org/10.1016/j.ejmech.2020.112232.

Posters

(available on demand)

Introduction of a platform for preclinical profiling of drug conjugates: A case study with Sacituzumab Govitecan. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; 2023 Apr 14-19. Philadelphia: Cancer Research 2023;83 (7_Suppl):Abstract nr. 4895. 

A systems biology approach combining ProLiFiler and Cancer Data Miner for an enhanced preclinical characterization of the WEE-1 inhibitor Adavosertib. In: Proceedings of the AACR Annual Meeting 2022. Cancer Res 2022;82(12_Suppl):Abstract nr 1132.

ProLiFiler and Cancer Data Miner, combined platforms for preclinical investigation to scrutinize impact of inhibitors on the KRAS, PI3K and MDM2 signaling pathways. In: Proceedings of the AACR Annual Meeting 2021; Cancer Res 2021;81(13_Suppl):Abstract nr 1027.

MACC1 overexpression in colorectal cancer is driven by chromosomal instability and is associated with molecular subtype. In: Proceedings of the AACR Annual Meeting 2021; Cancer Res 2021;81(13_Suppl):Abstract nr 2879. ​

Identification of novel targets for the treatment of pancreatic cancer patients. In: Proceedings of the AACR Annual Meeting 2021; AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1173.

Identification of a promising renal cell carcinoma target using a unique in silico approach. In: Proceedings of the AACR Annual Meeting 2021; Cancer Res 2021;81(13_Suppl):Abstract nr LB107.

An advanced in silico drug discovery platform, 4HF Biotec’s Data miner for identifying novel targets for tumors and tumor-stroma  European journal of cancer (Oxford, England: 2020) 138:S27 10.1016/S0959-8049(20)31137-0

The use of 4HF Cancer Data Miner platform for an in Silico pharmacogenomic study predicting tumor response to the CDK4/6 inhibitor Palbociclib In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C075. doi:10.1158/1535-7163.TARG-19-C075

Strong anti-tumor activity of MEK inhibitor GDC-0623 and determination of predictive biomarkers. In: Proceedings AACR Annual Meeting 2019; Atlanta, GA. Cancer Res 2019;79(13 Suppl):Abstract nr 2196.

4HF Cancer Data Miner platform for an accelerated In Silico ADC target discovery and evaluation. October 8 -11, 201910th Annual World ADC, San Diego

Broad spectrum activity of the MDM2 inhibitor MI-773 in hematologic and solid cancer cell lines in-vitro and determination of predictive biomarkers. In: Proceedings AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, Mol Cancer Ther 2019;18(12 Suppl):Abstract nr C060. doi:10.1158/1535-7163.TARG-19-C060

Broad spectrum activity of the BET inhibitor GSK 1324726A in hematologic and solid cancer cell lines in-vitro and determination of associated predictive biomarkers. In: Proceedings AACR Annual Meeting 2019; Atlanta, Cancer Res 2019;79(13 Suppl):Abstract nr 3074.

Broad spectrum activity of Sabutoclax in haematological and solid cancer cell lines is associated with defined biomarkers”; Section “Molecular Targeted Agents” on November 13, 2018; #PB-039 4HF Biotec participated in the 30th EORTC-NCI-AACR

KRAS gene mutations are associated with tumor resistance toward the LN1222/AD736 p38 inhibitor. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B167.